Abstract: Methods, systems, and devices are provided for measuring dark adaptation of one or both eyes of a patient, and more particularly, for measuring dark adaptation with a mobile device application. An exemplary method includes exposing an eye of a patient to a light source to bleach a retinal location of the eye, displaying on a mobile device a figure with a luminance and waiting until the patient communicates with the mobile device to acknowledge that the patient can see the figure, measuring and recording a level of the luminance and a time period between first displaying the figure and the patient communicating with the mobile device, continuing to display additional figures with decreasing luminance one at a time, and determining by a processor dark adaptation measurements of the patent based on the measured and recorded luminance and time periods.

Abstract: Methods are described for predicting ancestral sequences for viruses or portions thereof. Also described are predicted ancestral sequences for adeno-associated virus (AAV) capsid polypeptides. The disclosure also provides methods of gene transfer and methods of vaccinating subjects by administering a target antigen operably linked to the AAV capsid polypeptides.

Abstract: This disclosure describes compositions, methods, and systems for constructing defined variation in a contiguous functional genetic unit in association with a unique sequence identifier (“a barcode”) in a combinatorial manner.

Abstract: Methods, systems, and devices are provided for measuring eye refraction without a lens, and more particularly, for measuring eye refraction with a mobile device application. An exemplary method includes measuring a distance between a patient and a mobile device, presenting to the patient one or more visual targets sized and shaped to represent perfect vision such as by using Vernier targets or grating targets, instructing the patient to indicate whether the patient can accurately read the visual targets and, if not, to move closer to the mobile device until the patient can accurately read the visual targets, calculating a vision prescription for the patient based on the visual targets and a final distance between the patient and the mobile device, and displaying the vision prescription for the patient.

Abstract: This disclosure provides compositions and methods for altering or changing the tissue tropism, e.g., liver tropism, of adeno-associated viruses (AAV).

Abstract: Methods and compositions are provided that can be used to modify the assembly activating protein (AAP)-dependence of an adeno-associated virus (AAV).

Abstract: Methods, systems, and devices are provided for measuring dark adaptation of one or both eyes of a patient, and more particularly, for measuring dark adaptation with a mobile device application. An exemplary method includes exposing an eye of a patient to a light source to bleach a retinal location of the eye, displaying on a mobile device a figure with a luminance and waiting until the patient communicates with the mobile device to acknowledge that the patient can see the figure, measuring and recording a level of the luminance and a time period between first displaying the figure and the patient communicating with the mobile device, continuing to display additional figures with decreasing luminance one at a time, and determining by a processor dark adaptation measurements of the patent based on the measured and recorded luminance and time periods.

Abstract: Methods, systems, and devices are provided for measuring eye refraction without a lens, and more particularly, for measuring eye refraction with a mobile device application. An exemplary method includes measuring a distance between a patient and a mobile device, presenting to the patient one or more visual targets sized and shaped to represent perfect vision such as by using Vernier targets or grating targets, instructing the patient to indicate whether the patient can accurately read the visual targets and, if not, to move closer to the mobile device until the patient can accurately read the visual targets, calculating a vision prescription for the patient based on the visual targets and a final distance between the patient and the mobile device, and displaying the vision prescription for the patient.

Abstract: A device includes a frame, a rotatable housing and a permanent magnet. The frame is configured to be worn adjacent an eye region of a wearer. The rotatable housing is coupled to the frame. The permanent magnet is coupled to the rotatable housing and includes a first surface having a first static magnetic polarity and a second surface having a second static magnetic polarity opposite the first static magnetic polarity. The rotatable housing is arranged to rotate the permanent magnet between a first position orienting the first surface towards the eye region of the wearer and a second position orienting the second surface towards the eye region of the wearer. Related apparatus, systems, techniques and articles are also described.

Abstract: This application discloses ophthalmic formulations and methods for treating and preventing corneal haze and scarring with an hepatocyte growth factor (HGF) agent.

Abstract: The present subject matter provides compositions, formulations and methods for preventing or reducing proliferation or migration of retinal cells or epithelial to mesenchymal transition in ocular cells or cells from other tissues.

Abstract: Provided herein are vaccines against coronavirus that utilize adeno-associated virus (AAV) for delivery.

Abstract: The invention provides compositions and methods for treating optic neuropathic disorders.

Abstract: The present subject matter provides, inter alia compositions, formulations, and methods for inhibiting, treating, and preventing small vessel diseases.

Abstract: A method for reducing neovascularization in an ocular tissue is carried out by contacting the tissue with an inhibitor of endomucin expression or activity.

Abstract: The invention provides compositions and methods for preserving, restoring, or enhancing vision of a subject by administering compositions to an injured or diseased eye.

Abstract: Methods and systems providing adaptive assessment of a physical subject to efficiently collect assessment data and modify an assessment schedule based on the analyses. The methods and systems can control the timing of each assessment in order to collect data at times and under conditions that are most informative about the physical subject. Such adaptive methods and systems significantly minimize the frequency of data collection without loss in accuracy or precision and can increase test reliability through reduction in redundancy. The ability to estimate an unknown, underlying function using a small number of free parameters that remain constant regardless of the number of data points being estimated substantially reduces the error of the function estimate. Because estimates of the measurement error are achieved with a minimum of sampled assessments, and with great accuracy, the statistical power of clinical trials, for example, can be greatly increased.

Abstract: The invention provides ocular formulations and features a nano-emulsion composition, e.g., a nano-emulsion comprising a CBF?-RUNX1 inhibitor. The composition comprises a particle with a length of less than 200 nanometers in at least one dimension.

Abstract: Systems and methods of treating meibomian and sebaceous gland dysfunction. The methods include reducing oxygen concentration in the environment of one or more dysfunctional meibomian and sebaceous glands, thereby restoring a hypoxic status of one or more dysfunctional meibomian and sebaceous glands. The reducing of the oxygen concentration is accomplished by restricting blood flow to the one or more dysfunctional meibomian and sebaceous glands and the environment of one or more dysfunctional meibomian sebaceous glands. The restricting of the blood flow is accomplished by contracting or closing one or more blood vessels around the one or more dysfunctional meibomian or sebaceous glands. The methods also include giving local or systemic drugs that lead to the generation of hypoxia-inducible factors in one or more dysfunctional meibomian and sebaceous glands.

Abstract: The disclosure relates to compositions containing allyl isothiocyanate and methods of use thereof for stimulating tearing in a subject to treat dry eye.